It’s always unfortunate when mistakes like improper prescriptions happen. Somewhere along the line there was miscommunication, and sometimes neglect, by the prescribing doctor or the pharmacy. Since early this year the Federal Drug Authority has been issuing the warning against using cough medicines on young children because it can lead to life-threatening events and death. This latest news bears that tragic consequence.
Last week, makers of Tussionex Pennkinetic Extended-Release Suspension, the Belgian pharmaceutical group UCB SA, revealed the deaths of five children under six who had taken the medicine. The prescription cough medicine is approved only for adults and children age six and older. The Federal Drug Authority issued a warning that improper prescription for children under six and/or a dosing frequency of less than 12 hours in adults, adolescents or older children can lead to life-threatening breathing problems and death.
With this revelation, a revised drug label will now contain stronger warning and the need for accurate measurement and dosing. In light of this tragedy, the professions who handle our health must be more vigilant to follow prescription labels and warnings. And, I must add, no less than parents must read the accompanying labels as well.
Technorati Tags:
Tussionex Pennkinetic Extended-Release Suspension,
cough medicine,
prescription,
overdose,
death,
tragedy,
pharmaceutical,
pharmacy,
federal drug authority,
FDA,
warning,
labelShare This
